Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Karuna Therapeutics (NASDAQ: KRTX) will hold a conference call and webcast on May 4, 2023, at 8:00 a.m. ET to discuss its first quarter 2023 financial results and provide a general business update.
The live webcast will be available on the Investor Relations page of Karuna’s website, and a replay will be accessible for up to 30 days after the event. Karuna Therapeutics focuses on developing innovative treatments for psychiatric and neurological disorders, aiming to address the unmet needs of patients facing these challenges.
Karuna Therapeutics, Inc. (NASDAQ: KRTX) has successfully closed its underwritten public offering of 2,851,299 shares of common stock, including 371,908 shares purchased by underwriters at a public offering price of $161.33 each. The offering generated approximately $460 million in gross proceeds for the company, prior to underwriting discounts and estimated expenses. The shares were offered under an effective shelf registration statement previously filed with the SEC. Goldman Sachs, J.P. Morgan, and Morgan Stanley led the offering as joint book-running managers.
Karuna Therapeutics, Inc. (NASDAQ: KRTX) announced its participation in the Stifel 2023 CNS Days on March 29, 2023, at 8:00 a.m. ET. During the event, management will present updates on their innovative biopharmaceutical efforts aimed at developing transformative treatments for psychiatric and neurological conditions. A live webcast of the presentation will be accessible on the company's Investor Relations page, with a replay available for 30 days post-event. Karuna is committed to advancing effective therapies to improve patient outcomes in severe mental health disorders.
Karuna Therapeutics (NASDAQ: KRTX) has announced a public offering of 2,479,391 shares of common stock, priced at $161.33 per share, aiming to raise approximately $400 million. The transaction is anticipated to close on or about March 24, 2023, pending customary conditions. The underwriters have an option to purchase an additional 371,908 shares. The offering will be conducted under a previously filed effective shelf registration statement with the Securities and Exchange Commission (SEC).
Karuna Therapeutics has announced a public offering of $400 million of common stock, with an additional $60 million option for underwriters. The offering will be managed by Goldman Sachs, J.P. Morgan, and Morgan Stanley. Proceeds will support the company’s initiatives in psychiatric and neurological conditions. The offering is subject to market conditions, and specifics will be detailed in a prospectus supplement filed with the SEC. This initiative highlights Karuna's commitment to expanding its capabilities, though actual outcomes hinge on market acceptance and completion of the offering.